SCOTTSDALE, Ariz., June 15, 2009 (GLOBE NEWSWIRE) -- Medicis Pharmaceutical Corporation (NYSE:MRX) ("the Company"), the parent company of Medicis Technologies Corporation and Medicis Aesthetics Canada Ltd., today announced that Health Canada has issued a Medical Device License (MDL) authorizing the sale of the LIPOSONIX(TM) System Model 1 in Canada. The LIPOSONIX system is designed to utilize high intensity focused ultrasound energy to reduce subcutaneous abdominal adipose tissue in the treatment zone to provide a non-invasive, non-surgical approach to body contouring. The Company plans for the LIPOSONIX system to be marketed in Canada by Medicis Aesthetics Canada.
